

Published in final edited form as:

Methods Mol Biol. 2015 ; 1266: 171–184. doi:10.1007/978-1-4939-2272-7_12.

Site-specific biotinylation of purified proteins using BirA

Michael Fairhead and Mark Howarth

Department of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK

Summary

The binding between biotin and streptavidin or avidin is one of the strongest known non-covalent biological interactions. The (strept)avidin-biotin interaction has been widely used for decades in biological research and biotechnology. Therefore labeling of purified proteins by biotin is a powerful way to achieve protein capture, immobilization, and functionalization, as well as multimerizing or bridging molecules. Chemical biotinylation often generates heterogeneous products, which may have impaired function. Enzymatic biotinylation with *E. coli* biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide, giving a homogeneous product with high yield. AviTag can conveniently be added genetically at the N-terminus, C-terminus or in exposed loops of a target protein. We describe here procedures for AviTag insertion by inverse PCR, purification of BirA fused to glutathione-S-transferase (GST-BirA) from *E. coli*, BirA biotinylation of purified protein, and gel-shift analysis by SDS-PAGE to quantify the extent of biotinylation.

Keywords

Neutravidin; Streptavidin-biotin; Femtomolar; Nanotechnology; Bionanotechnology

1. Introduction

Biotin is a cofactor for carboxylase enzymes, present in all living organisms (1). Streptavidin binds to biotin with a K_d of 4×10^{-14} M (2). Streptavidin-biotin binding is rapid, specific and can still occur under conditions where most other proteins have denatured, such as high temperatures or 6 M guanidinium hydrochloride or 1% sodium dodecyl sulfate (SDS) (3). A breakthrough for the use of biotin for protein modification was harnessing the cell's natural machinery for biotin conjugation, using the *E. coli* enzyme BirA to achieve precise biotin modification (4). The natural substrate of BirA is the Biotin Carboxyl Carrier Protein (BCCP), requiring fusion of at least 75 residues to the target protein (4). However, phage display selection enabled the development of the AviTag (also known as the Acceptor Peptide, AP), which is superior to BCCP as a BirA substrate but only 15 amino acids in length (5) (see Fig. 1), so extending the range of protein sites amenable to site-specific enzymatic biotinylation.

More recent work has established that BirA can biotinylate such substrate peptides specifically in the cytosol (6), secretory pathway, and at the cell surface in mammalian and invertebrate systems (7,8,9,10). A detailed protocol for labeling with BirA at the mammalian cell surface for fluorescent imaging has recently been published (11).

Biotinylation of purified proteins has been applied in a wide range of areas of biochemistry and cell biology (*see* Fig. 2):

- Tetramerization - enhancing the avidity of ligand binding. For example, MHC class I tetramerized by streptavidin enabled stable binding to the T cell receptor and so allowed monitoring of the immune response and isolation of anti-pathogen or anti-cancer T cells (12).
- Bridging - for nanoassembly, streptavidin is often used as a bridge between one biotinylated protein and another biotinylated molecule, such as DNA, sugars, lipids or small-molecule drugs (13).
- Immobilization - giving precise attachment that is stable over time, to a wide range of pH values, and to force. BirA-biotinylated proteins are commonly used for capture on chromatography columns, chips (e.g. for surface plasmon resonance or next generation sequencing) (14), atomic force microscope tips (15), or nanoparticles (e.g. quantum dots or magnetic particles) (16).
- Sensitive detection - an *in vitro* biotinylated protein can be added to cells and subsequently recognized with high affinity by streptavidin conjugates (17). Use of monovalent streptavidin facilitates efficient measurement of the absolute number of biotin binding sites on cells (16).

Further developments

An important advance in BirA labeling is its use for electron microscopy (18). Biotin ligase from *E. coli* or other species can also ligate to a peptide tag biotin analogs, including desthiobiotin for reversible streptavidin binding (19), or analogs containing functional groups for bio-orthogonal reaction: keto (20), azido and alkyne groups (21). However, only small changes to the structure of biotin could be tolerated by biotin ligase and so the related ligase LplA has proved more amenable to direct incorporation of fluorophores (22).

Engineering of streptavidin is important in extending the usefulness of BirA-labeling; in particular variants with controlled valency (e.g. monovalent streptavidin, mSA), enabling precise control over assembly of biotin conjugates (11,23). In addition, we generated a streptavidin variant with 10-fold lower off-rate for biotin and enhanced thermal stability (traptavidin) (24,25).

New applications of BirA have been for labeling specific protein populations – by targeting BirA to a specific chromatin-associated protein, particular AviTag-linked nucleosome populations were biotinylated (26). By targeting BirA to one synaptic membrane, AviTag-proteins on the opposite synaptic membrane were biotinylated, allowing imaging of specific protein-protein interactions at synapses (27). Through expressing a BirA-substrate peptide on a nuclear envelope protein and BirA in specific tissues of *Arabidopsis thaliana*,

Caenorhabditis elegans or *Drosophila melanogaster*, nuclei from specific cell-types could be isolated by streptavidin pull-down (28,29). Also the use of enzymes to achieve *promiscuous* biotinylation (a BirA mutant or a peroxidase) has enabled labeling of untagged proteins in particular cellular regions or compartments (30,31,32).

Limits of BirA protein labeling

The convenience and high yield of BirA labeling must be considered against certain limitations:

- a peptide tag must be introduced into the target protein.

For site-specific biotinylation while only changing a single residue, suppressor tRNA bearing a biotinylated amino acid can be used (although some protein locations were not well tolerated) (33). However, biotinylation via artificial amino acid incorporation brings disadvantages of more complex expression and of uncertainty in percentage incorporation- the initial assessment of biotinylation yield in *Xenopus* oocytes was done indirectly via electrophysiology and radioactive streptavidin binding (33). p-Aminophenylalanine-linked biotin conjugates on tRNA showed improved protein incorporation in cell-free translation (34) (reagents are available from RiNA GmbH or Cosmo Bio Co. Ltd.). Biotinylation can also be achieved directly at the N-terminus, such as with subtiligase (35), or at the C-terminus using inteins (36).

- the binding partner of biotin, streptavidin or avidin, does not interact covalently and is not a good fusion partner.

Covalent linkage to peptide tags can now be achieved using split inteins (37,38), sortase (39) and SpyCatcher (40), although they have not yet demonstrated the high sensitivity of detection shown by streptavidin or avidin. A monomeric streptavidin has been developed that is suitable as a fusion tag (41). A key future development will be to improve monomeric streptavidin's binding affinity to that of the original tetrameric streptavidin.

2. Materials

2.1 Equipment

1. Incubators and shakers appropriate for growing bacterial cultures.
2. Centrifuges: floor-standing centrifuge capable of spinning at 5,000 g on 1 L bacterial culture and bench-top centrifuge capable of spinning 1.5 mL tubes at 20,000 g.
3. Sonicator or other cell-disrupting apparatus (e.g. French press).
4. UV-Vis spectrophotometer or Nanodrop for protein quantification.
5. Electrophoresis apparatus for running SDS-PAGE.
6. PCR machine.

2.2 Proteins, DNA and other Reagents

1. Streptavidin (commercially available from several sources including Thermo Scientific, Sigma and Roche) (*see* Note 1).
2. pGEX-GST-BirA plasmid (42) (a kind gift from Chris O'Callaghan, University of Oxford); alternative expression vectors containing Maltose Binding Protein-BirA or His₆-BirA are available through Addgene (www.addgene.org).
3. Complete Protease Inhibitor Cocktail tablets (Roche) for inhibiting *E. coli* proteases during purification of GST-BirA.
4. 100 mM PMSF solution: 17.4 mg of phenylmethylsulfonyl fluoride (PMSF) in 1 mL of isopropanol. Store at –20 °C. (CAUTION: PMSF is toxic. PMSF should be added to the aqueous buffer just prior to use, as it has a short half-life in aqueous solutions.)
5. Glutathione-HiCap resin for purification of GST-tagged proteins (Qiagen).
6. Target protein with AviTag peptide sequence (*see* Note 2).
7. KOD hot start polymerase (Merck Millipore)
8. T4 DNA ligase (NEB)
9. T4 polynucleotide kinase (NEB)
10. DpnI (NEB).
11. 50 mM D-Biotin solution: 12.2 mg of D-biotin in 1 mL of anhydrous DMSO. Store at –20 °C.
12. 100 mM ATP solution: 55.1 mg of adenosine 5'-triphosphate disodium salt hydrate in 1 mL MilliQ water. Store in aliquots at –80 °C (*see* Note 3).
13. 1 M magnesium chloride solution: 203 mg of magnesium chloride hexahydrate in 1 mL MilliQ water. Store at room temperature.
14. 100 mM DTT solution: 15.4 mg of dithiothreitol in 1 mL MilliQ water. Aliquot and store at –20 °C. Make freshly each week.

¹Instead of streptavidin, other high affinity biotin-binding proteins may be used to bind to enzymatically biotinylated proteins. Avidin is not recommended because its positive charge promotes non-specific binding to cells and DNA, but neutravidin should be satisfactory for many applications (47).

²Several peptide sequences have been described for BirA-mediated biotinylation. These are based on those first described by Schatz and coworkers (48,5), who found a 13 amino acid peptide to be the minimal substrate peptide for BirA (LX\$IFEAQKIEWR, where X = any and \$ = any but not L, V, I, W, F or Y). This sequence was further optimized to improve the rate of biotinylation, resulting in AviTag (GLNDIFEAQKIEWHE). AviTag works at either the N or C terminus of the target protein (46). A close 15 residue relative, termed BioTag (ALNDIFEAQKIEWHA), is also used in some papers (48,10). BLRP (Biotin ligase recognition peptide) contains a core of AviTag and is 23 residues: (MAGGLNDIFEAQKIEWHEDTGGG) (5,49). Another popular target is the 15 residue "BirA Substrate Peptide" (BSP), LHHILDAQKMVWNHR (48,42). A further consideration is whether some flexibility should be added between the AviTag and the target protein. We would suggest including a flexible two residue GS linker between the AviTag and the target protein or any other surrounding peptide tag or domain. In the unlikely event that constructs with N-terminal or C-terminal AviTag do not enable biotinylation or yield low amounts of protein, first try increasing the spacer to 6 residues and then it may be worth trying BSP (42). Vectors are also available containing N- or C-terminal AviTag sequences from Avidity or from Genecopoeia (for bacterial, mammalian or cell-free expression; some plasmids have BirA downstream for coexpression).

³Prepare single-use aliquots: freeze-thawing damages ATP stocks. Also, ATP will be hydrolyzed at pH greater than 8.5.

15. 420 mM IPTG solution: 1 g isopropyl- β -D-thiogalactopyranoside in 10 mL MilliQ water. Syringe-filter and store at -20°C .
16. 100 mg/mL Ampicillin solution: 1 g of ampicillin sodium salt in 10 mL MilliQ water. Syringe-filter and store at -20°C .
17. 20% glucose solution: 200 g/L of D-glucose in MilliQ water. Autoclave and store at room temperature.

2.3 Buffers, Media and Cells

1. Phosphate buffered saline (PBS): 1.44 g/L di-sodium hydrogen phosphate, 0.24 g/L potassium di-hydrogen phosphate, 0.2 g/L KCl, 8 g/L NaCl, pH 7.4.
2. PBS-L buffer: PBS, 1 mM EDTA, 1 mM DTT, 0.1 mg/mL lysozyme, 1% Triton X-100 (make fresh each day).
3. PBS-EW buffer: PBS, 1 mM DTT and 1 mM EDTA.
4. Elution buffer: 50 mM Tris.HCl pH 8.0, 0.4 M NaCl, 50 mM reduced glutathione, 1 mM DTT. Make this buffer fresh on each occasion.
5. Luria Bertani broth (LB): 10 g/L bacto-tryptone, 5 g/L yeast extract, 5 g/L NaCl. Autoclave and store at room temperature.
6. *E. coli* strain suitable for protein expression, e.g. BL21 [DE3] RIPL (Agilent).
7. 2 \times SDS-PAGE buffer (non-reducing): 4% SDS, 20% glycerol, 0.12 M Tris.HCl pH 6.8. Store aliquots at -20°C .

3. Methods

The methods described below utilize a glutathione-S-transferase-BirA fusion protein, but are adaptable to His₆-tagged or Maltose Binding Protein (MBP) fusion constructs. All three constructs express well but GST-BirA can be efficiently removed from the biotinylated substrate after reaction, by passing through glutathione-agarose.

3.1 GST-BirA production

1. Transform an appropriate *E. coli* expression strain (e.g. BL21) with the pGEX-GST-BirA plasmid.
2. Grow a 10 mL overnight culture from a single colony in LB plus 10 μL of 100 mg/mL ampicillin and 200 μL of 20% glucose.
3. Use 8 mL of the overnight culture to inoculate 800 mL LB plus 0.8 mL 100 mg/mL ampicillin and 30 mL 20% glucose in a 2 L baffled flask.
4. Grow at 37°C with 200 rpm shaking to an OD₆₀₀ of 0.5.
5. Induce protein expression by addition of 0.8 mL of 420 mM IPTG solution.
6. Continue growth at 25°C with 200 rpm shaking overnight.
7. Harvest cells by centrifugation for 10 minutes at 5,000 g at 4°C .

8. Resuspend cells in 15 mL of PBS and freeze at -80°C .
9. Thaw cells on ice and add 0.17 mL of 10 mg/mL lysozyme, one Complete Protease Inhibitor Cocktail tablet, 0.17 mL of 100 mM PMSF, 1.7 mL of 10% Triton X-100, 0.17 mL of 100 mM EDTA and 0.17 mL of 100 mM DTT.
10. Incubate 30 minutes on ice and freeze again at -80°C to help cell lysis.
11. Thaw cells and add 15 mL cold PBS-L buffer. Hereafter, keep the sample at 4°C at all stages.
12. Sonicate to reduce viscosity (e.g. 3-5 \times 30 second bursts on ice). (CAUTION: wear appropriate ear protection.)
13. Centrifuge lysed cells at 20,000 g for 30 minutes.
14. Collect the supernatant and add 1 mL of glutathione-HiCap resin to the supernatant, mixing end-over-end for 30 minutes at 4°C .
15. Centrifuge resin for 2 minutes at 1,000 g and discard supernatant.
16. Wash resin with 30 mL PBS-EW. Centrifuge resin for 2 minutes at 1,000 g and repeat the wash.
17. Elute GST-BirA with 2 mL Elution buffer and incubate for 30 minutes at 4°C .
18. Centrifuge resin for 2 minutes at 1,000 g and collect supernatant.
19. Check purity by SDS-PAGE (14% polyacrylamide) (*see* Fig. 3) and concentration via OD_{280} (GST-BirA has an ϵ_{280} of $90,550 \text{ M}^{-1}\text{cm}^{-1}$).
20. Concentrate by ultrafiltration to $\sim 50 \mu\text{M}$ and store in single-use aliquots at -80°C . Concentrations of GST-BirA much greater than $50 \mu\text{M}$ may crash out. Final yield should be 10-20 mg/L of expression culture. After thawing, aliquots stored at 4°C should be used within 1 week.

3.2 Generation of AviTag protein constructs

A variety of standard molecular biology methods can be used to add the AviTag (*see* Note 2) to an appropriate site in a target protein (*see* Note 4). For certain experiments it may also be valuable to clone a negative control peptide that is not biotinylated by BirA (*see* Note 5). We suggest using a modified inverse PCR mutagenesis (43) (*see* Fig. 4) or Site-directed Ligase-Independent Mutagenesis (SLIM) reaction (44), which enables the insertion of the substrate peptide without requiring any restriction sites nearby. Below is an example inverse PCR mutagenesis protocol.

⁴Selected examples of successful biotinylation following BirA-substrate peptide insertion in protein loops: the *E. coli* flagellar hook (50), Cystic Fibrosis Transmembrane Regulator (CFTR) (51), and Dicer (52). For Dicer, Lau et al. use streptavidin to highlight features for Cryoelectron Microscopy and describe several functional and some non-functional peptide insertion sites, advising insertion in short loops disordered in the crystal structure or less highly conserved (52).

⁵The Lys to Ala mutant of AviTag (GLNDIFEQAIEWHE) serves as an effective negative control sequence that will not be biotinylated (20,8). Note that AviTag-fusions expressed in *E. coli* may have some biotinylation from the cell's own BirA, but this reaction may often not reach completion, even in strains with BirA overexpressed (AVB101, Avidity) (53). Also, adding BirA to an AviTag-fusion in the absence of ATP or biotin may still allow some biotinylation to take place, because of biotin-AMP pre-bound to the purified protein (8,20).

1. Forward and reverse primers for peptide insertion should be designed to each have 18-25 bp matching the parental sequence and have a calculated annealing temperature (to the parent sequence) of at least 55 °C (*see* Fig. 4).
2. Assemble the following reaction mixture in a PCR tube: 29.5 µL MilliQ water, 1.5 µL DMSO, 5 µL KOD polymerase buffer, 5 µL 25 mM MgSO₄, 1 µL 15 µM forward primer, 1 µL 15 µM reverse primer, 1 µL 100 ng/µL template plasmid DNA, 5 µL 2 mM dNTP mix and finally 1 µL KOD hot start polymerase.
3. After transferring the tube to a PCR machine, perform an initial denaturing step of 3 minutes at 95 °C, followed by 12 cycles of: 95 °C for 30 seconds, 55 °C for 30 seconds and 68 °C for 30 seconds/kb of target plasmid DNA.
4. Add 1 µL of 20 U/µL DpnI enzyme to the PCR mix and incubate at 37 °C for 1 hour.
5. Run an aliquot of the reaction on a 0.7% agarose gel to confirm the success and fidelity of the PCR (a clean band should be observed corresponding to the size of the linearized target plasmid DNA).
6. To 2 µL of the PCR product, add 14 µL MilliQ water, followed by 2 µL of 10× T4 DNA ligase buffer, 1 µL T4 polynucleotide kinase and 1 µL of T4 DNA ligase.
7. Incubate the sample for 1 hour at room temperature and transform an appropriate strain of competent *E. coli* (e.g. DH5α, XL1-Blue, JM109) with 5 µL of the ligation reaction. Cells with competency of at least 10⁷ cfu/µg should be sufficient.
8. After validating the construct by sequencing, the AviTag-fused protein can be overexpressed in the appropriate cell system (commonly *E. coli*, baculovirus or HEK 293T cells).

3.3 Biotinylation of AviTag-fused proteins using BirA

1. To 100 µM AviTag-fused protein in 952 µL of PBS, add 5 µL 1 M magnesium chloride, 20 µL 100 mM ATP, 20 µL 50 µM GST-BirA and 3 µL 50 mM D-Biotin (*see* Note 6).
2. Incubate sample for 1 hour at 30 °C with gentle mixing on a rocking platform.
3. Add the same amount of fresh biotin and GST-BirA and incubate for a further hour.
4. GST-BirA may be removed by incubation of the sample with 0.1 mL of a 50% slurry of glutathione-HiCap resin in PBS for 30 minutes at room temperature, followed by centrifugation and collection of the supernatant (45).
5. Dialyze the sample into PBS or other suitable buffer, for storage and to remove the excess biotin.

⁶Other buffers may be used for biotinylation. Schatz et al. prefer 50 mM bicine pH 8.3, maintaining low [NaCl] (46), but in our hands biotinylation in PBS is still quantitative. It is preferable to have the AviTag-fusion at concentration > 40 µM when incubating with BirA; otherwise biotinylation is less efficient (46). The biotinylation reaction may be run on a smaller scale; the only issue is that losses from dialysis become more significant when working with a low total amount of protein.

6. The biotinylation of the target protein is generally irreversible *in vitro*; apparent loss of biotinylation is most likely to reflect proteolysis separating the biotinylation site from the rest of the target protein.

3.4 Testing the extent of protein biotinylation by a streptavidin gel-shift

The efficiency of the biotinylation reaction has been examined by Western blotting (6) or other enzymatic or ligand-displacement assays (46), but these approaches are time-consuming and only indirectly allow quantitation. A rapid and easily quantified alternative is to saturate the target protein with streptavidin and study the gel-shift in SDS-PAGE (*see* Fig. 5). Provided the gel does not get excessively warm during the run, streptavidin will retain its native tetramer structure and remain bound to biotin conjugates under normal SDS-PAGE conditions (16). A streptavidin monomer (i.e. one biotin binding site) has a calculated ϵ_{280} of $41,940 \text{ M}^{-1} \text{ cm}^{-1}$.

1. Prepare a PCR tube containing 5 μL of 10 μM biotinylated target protein and add 10 μL of 2 \times SDS-PAGE buffer.
2. Heat samples at 95 $^{\circ}\text{C}$ for 5 minutes in a PCR block with a heated lid.
3. Allow the sample to cool to room temperature and briefly centrifuge.
4. **After** this boiling and cooling, add 5 μL of PBS containing a small molar excess (2- to 5-fold) of streptavidin to the samples and incubate at room temperature for 5 minutes (it is advisable to run a control lane of streptavidin without the target protein).
5. Run samples on an appropriate SDS-PAGE gel (the streptavidin tetramer, running at 50-60 kDa, is clearly visible on 10, 12, 14, 16 % gels) (*see* Note 7).
6. Stain the gel with InstantBlue or Coomassie blue and visualize. If desired, quantify the degree of biotinylation by densitometry, measuring the change in intensity of the relevant protein band with and without addition of streptavidin (*see* Note 8). In the lane containing biotinylated protein and streptavidin, the presence of a band corresponding to free streptavidin verifies that streptavidin was indeed provided in excess and so all biotinylated protein will have been bound. Streptavidin may sometimes increase in mobility upon binding to biotin conjugates, according to the size and charge of the biotin conjugate (*see* Fig. 5).

Acknowledgement

This work was supported by the Biotechnology and Biological Sciences Research Council (BBSRC). We thank Jayati Jain (Howarth laboratory) for providing Fig. 5.

⁷If your target protein happens to have exactly the same mobility as streptavidin, use a different percentage gel. The target protein is unfolded and will run according to its molecular weight, but streptavidin remains folded and runs at a different height on different percentage gels.

⁸With incomplete biotinylation, it is possible to purify the biotinylated fraction using monomeric avidin (a chemically modified version of avidin with reversible biotin binding) (45), but we would suggest that it is preferable to modify the biotinylation reaction until the reaction does go to completion.

References

1. Chapman-Smith A, Cronan JE Jr. In vivo enzymatic protein biotinylation. *Biomol Eng.* 1999; 16:119–125. [PubMed: 10796994]
2. Green NM. Avidin and streptavidin. *Methods Enzymol.* 1990; 184:51–67. [PubMed: 2388586]
3. Sano T, Vajda S, Cantor CR. Genetic engineering of streptavidin, a versatile affinity tag. *J Chromatogr B Biomed Sci Appl.* 1998; 715:85–91. [PubMed: 9792500]
4. Cronan JE Jr. Biotinylation of proteins in vivo. A post-translational modification to label, purify, and study proteins. *J Biol Chem.* 1990; 265:10327–10333. [PubMed: 2113052]
5. Beckett D, Kovaleva E, Schatz PJ. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. *Protein Sci.* 1999; 8:921–929. [PubMed: 10211839]
6. de Boer E, et al. Efficient biotinylation and single-step purification of tagged transcription factors in mammalian cells and transgenic mice. *Proc Natl Acad Sci U S A.* 2003; 100:7480–7485. [PubMed: 12802011]
7. Parrott MB, Barry MA. Metabolic biotinylation of secreted and cell surface proteins from mammalian cells. *Biochem Biophys Res Commun.* 2001; 281:993–1000. [PubMed: 11237761]
8. Howarth M, Takao K, Hayashi Y, Ting AY. Targeting quantum dots to surface proteins in living cells with biotin ligase. *Proc Natl Acad Sci U S A.* 2005; 102:7583–7588. [PubMed: 15897449]
9. Yang J, Jaramillo A, Shi R, Kwok WW, Mohanakumar T. In vivo biotinylation of the major histocompatibility complex (MHC) class II/peptide complex by coexpression of BirA enzyme for the generation of MHC class II/tetramers. *Hum Immunol.* 2004; 65:692–699. [PubMed: 15301857]
10. Ooi SL, Henikoff JG, Henikoff S. A native chromatin purification system for epigenomic profiling in *Caenorhabditis elegans*. *Nucleic Acids Res.* 2010; 38:e26. [PubMed: 19966274]
11. Howarth M, Ting AY. Imaging proteins in live mammalian cells with biotin ligase and monovalent streptavidin. *Nat Protoc.* 2008; 3:534–545. [PubMed: 18323822]
12. Sims S, Willberg C, Klenerman P. MHC-peptide tetramers for the analysis of antigen-specific T cells. *Expert Rev Vaccines.* 2010; 9:765–774. [PubMed: 20624049]
13. Valadon P, et al. Designed auto-assembly of nanostreptabodies for rapid tissue-specific targeting in vivo. *J Biol Chem.* 2010; 285:713–722. [PubMed: 19850928]
14. Williams JG, et al. An artificial processivity clamp made with streptavidin facilitates oriented attachment of polymerase-DNA complexes to surfaces. *Nucleic Acids Res.* 2008; 36:e121. [PubMed: 18723573]
15. Rakshit S, Zhang Y, Manibog K, Shafraz O, Sivasankar S. Ideal, catch, and slip bonds in cadherin adhesion. *Proc Natl Acad Sci U S A.* 2012; 109:18815–18820. [PubMed: 23112161]
16. Jain J, Veggiani G, Howarth M. Cholesterol loading and ultrastable protein interactions determine the level of tumor marker required for optimal isolation of cancer cells. *Cancer Res.* 2013; 73:2310–2321. [PubMed: 23378340]
17. Sung K, Maloney MT, Yang J, Wu C. A novel method for producing mono-biotinylated, biologically active neurotrophic factors: an essential reagent for single molecule study of axonal transport. *J Neurosci Methods.* 2011; 200:121–128. [PubMed: 21756937]
18. Viens A, et al. Use of protein biotinylation in vivo for immunoelectron microscopic localization of a specific protein isoform. *J Histochem Cytochem.* 2008; 56:911–919. [PubMed: 18574249]
19. Wu SC, Wong SL. Development of an enzymatic method for site-specific incorporation of desthiobiotin to recombinant proteins in vitro. *Anal Biochem.* 2004; 331:340–348. [PubMed: 15265740]
20. Chen I, Howarth M, Lin W, Ting AY. Site-specific labeling of cell surface proteins with biophysical probes using biotin ligase. *Nat Methods.* 2005; 2:99–104. [PubMed: 15782206]
21. Slavoff SA, Chen I, Choi YA, Ting AY. Expanding the substrate tolerance of biotin ligase through exploration of enzymes from diverse species. *J Am Chem Soc.* 2008; 130:1160–1162. [PubMed: 18171066]
22. Uttamapinant C, et al. A fluorophore ligase for site-specific protein labeling inside living cells. *Proc Natl Acad Sci U S A.* 2010; 107:10914–10919. [PubMed: 20534555]

23. Howarth M, et al. A monovalent streptavidin with a single femtomolar biotin binding site. *Nat Methods*. 2006; 3:267–273. [PubMed: 16554831]
24. Chivers CE, et al. A streptavidin variant with slower biotin dissociation and increased mechanostability. *Nat Methods*. 2010; 7:391–393. [PubMed: 20383133]
25. Chivers CE, Koner AL, Lowe ED, Howarth M. How the biotin-streptavidin interaction was made even stronger: investigation via crystallography and a chimaeric tetramer. *Biochem J*. 2011; 435:55–63. [PubMed: 21241253]
26. Lau PN, Cheung P. Elucidating combinatorial histone modifications and crosstalks by coupling histone-modifying enzyme with biotin ligase activity. *Nucleic Acids Research*. 2013; 41:e49. [PubMed: 23258705]
27. Liu DS, Loh KH, Lam SS, White KA, Ting AY. Imaging Trans-Cellular Neurexin-Neuroigin Interactions by Enzymatic Probe Ligation. *Plos One*. 2013; 8:e52823. [PubMed: 23457442]
28. Deal RB, Henikoff S. The INTACT method for cell type-specific gene expression and chromatin profiling in *Arabidopsis thaliana*. *Nat Protoc*. 2011; 6:56–68. [PubMed: 21212783]
29. Steiner FA, Talbert PB, Kasinathan S, Deal RB, Henikoff S. Cell-type-specific nuclei purification from whole animals for genome-wide expression and chromatin profiling. *Genome Research*. 2012; 22:766–777. [PubMed: 22219512]
30. Cronan JE. Targeted and proximity-dependent promiscuous protein biotinylation by a mutant *Escherichia coli* biotin protein ligase. *Journal of Nutritional Biochemistry*. 2005; 16:416–418. [PubMed: 15992681]
31. Roux KJ, Kim DI, Raida M, Burke B. A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells. *Journal of Cell Biology*. 2012; 196:801–810. [PubMed: 22412018]
32. Martell JD, et al. Engineered ascorbate peroxidase as a genetically encoded reporter for electron microscopy. *Nature Biotechnology*. 2012; 30:1143–+.
33. Gallivan JP, Lester HA, Dougherty DA. Site-specific incorporation of biotinylated amino acids to identify surface-exposed residues in integral membrane proteins. *Chemistry & Biology*. 1997; 4:739–749. [PubMed: 9375252]
34. Watanabe T, Muranaka N, Iijima I, Hoshida T. Position-specific incorporation of biotinylated non-natural amino acids into a protein in a cell-free translation system. *Biochemical and Biophysical Research Communications*. 2007; 361:794–799. [PubMed: 17678619]
35. Yoshihara HA, Mahrus S, Wells JA. Tags for labeling protein N-termini with subtiligase for proteomics. *Bioorg Med Chem Lett*. 2008; 18:6000–6003. [PubMed: 18762420]
36. Lesaichere ML, Lue RYP, Chen GYJ, Zhu Q, Yao SQ. Intein-mediated biotinylation of proteins and its application in a protein microarray. *Journal of the American Chemical Society*. 2002; 124:8768–8769. [PubMed: 12137509]
37. Carvajal-Vallejos P, Pallisse R, Mootz HD, Schmidt SR. Unprecedented rates and efficiencies revealed for new natural split inteins from metagenomic sources. *J Biol Chem*. 2012; 287:28686–28696. [PubMed: 22753413]
38. Shah NH, Dann GP, Vila-Perello M, Liu Z, Muir TW. Ultrafast protein splicing is common among cyanobacterial split inteins: implications for protein engineering. *J Am Chem Soc*. 2012; 134:11338–11341. [PubMed: 22734434]
39. Popp MW, Antos JM, Grotenbreg GM, Spooner E, Ploegh HL. Sortagging: a versatile method for protein labeling. *Nat Chem Biol*. 2007; 3:707–708. [PubMed: 17891153]
40. Zakeri B, et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. *Proc Natl Acad Sci U S A*. 2012; 109:E690–E697. [PubMed: 22366317]
41. Lim KH, Huang H, Pralle A, Park S. Stable, high-affinity streptavidin monomer for protein labeling and monovalent biotin detection. *Biotechnol Bioeng*. 2013; 110:57–67. [PubMed: 22806584]
42. O'Callaghan CA, et al. BirA enzyme: production and application in the study of membrane receptor-ligand interactions by site-specific biotinylation. *Anal Biochem*. 1999; 266:9–15. [PubMed: 9887208]
43. Gama L, Breitwieser GE. Generation of epitope-tagged proteins by inverse polymerase chain reaction mutagenesis. *Methods Mol Biol*. 2002; 182:77–83. [PubMed: 11768979]

44. Chiu J, March PE, Lee R, Tillett D. Site-directed, Ligase-Independent Mutagenesis (SLIM): a single-tube methodology approaching 100% efficiency in 4 h. *Nucleic Acids Res.* 2004; 32:e174. [PubMed: 15585660]
45. Saviranta P, Haavisto T, Rappu P, Karp M, Lovgren T. In vitro enzymatic biotinylation of recombinant fab fragments through a peptide acceptor tail. *Bioconjug Chem.* 1998; 9:725–735. [PubMed: 9815166]
46. Cull MG, Schatz PJ. Biotinylation of proteins in vivo and in vitro using small peptide tags. *Methods Enzymol.* 2000; 326:430–440. [PubMed: 11036656]
47. Marttila AT, et al. Recombinant NeutraLite avidin: a non-glycosylated, acidic mutant of chicken avidin that exhibits high affinity for biotin and low non-specific binding properties. *FEBS Lett.* 2000; 467:31–36. [PubMed: 10664451]
48. Schatz PJ. Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: a 13 residue consensus peptide specifies biotinylation in *Escherichia coli*. *Biotechnology (N Y).* 1993; 11:1138–1143. [PubMed: 7764094]
49. Zilberman D, Coleman-Derr D, Ballinger T, Henikoff S. Histone H2A.Z and DNA methylation are mutually antagonistic chromatin marks. *Nature.* 2008; 456:125–129. [PubMed: 18815594]
50. Brown MT, et al. Flagellar hook flexibility is essential for bundle formation in swimming *Escherichia coli* cells. *J Bacteriol.* 2012; 194:3495–3501. [PubMed: 22522898]
51. Bates IR, et al. Membrane lateral diffusion and capture of CFTR within transient confinement zones. *Biophys J.* 2006; 91:1046–1058. [PubMed: 16714353]
52. Lau PW, Potter CS, Carragher B, MacRae IJ. DOLORS: versatile strategy for internal labeling and domain localization in electron microscopy. *Structure.* 2012; 20:1995–2002. [PubMed: 23217681]
53. Li Y, Sousa R. Expression and purification of *E. coli* BirA biotin ligase for in vitro biotinylation. *Protein Expr Purif.* 2012; 82:162–167. [PubMed: 22227598]




Fig.1. Principle of BirA use. **(A)** Biotin ligase (BirA) reaction, covalently linking free biotin to the lysine of AviTag. **(B)** Advantage of labeling with BirA compared to labeling with amine-reactive biotin N-hydroxysuccinimide (NHS) esters, illustrated with regard to a Fab antibody fragment.




Fig. 2.
Common applications of BirA biotinylation of purified proteins.






Fig. 3. Expression and purification of GST-BirA. 14% SDS-PAGE with Coomassie staining of samples of the lysate (Lys) and soluble fraction (Sol) of *E. coli* expressing GST-BirA and varying amounts of the protein preparation purified with glutathione-resin.

**Fig. 4.**

Design of primers for AviTag insertion using the inverse PCR mutagenesis method.

**Fig. 5.**

Testing the extent of biotinylation by SDS-PAGE gel-shift. Coomassie-stained SDS-PAGE of an antibody fragment (Fab0.35) with an AviTag on the C-terminus of both the heavy and light chains. The lanes represent non-biotinylated Fab (nb), biotinylated Fab, biotinylated Fab with streptavidin (SA), and streptavidin alone. Streptavidin has 4 binding sites and so may associate with 1 or 2 chains of the biotinylated target, but this does not affect the calculation of the depletion of the original target protein band.